- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02774980
Cognitive Markers of Response to Treatment in Resistant Depression (DEP-ICOR)
Patients with depression are frequently treatment resistant. Clinical manifestations of depression are various, but cognitive dysfunctions are commonly present. Many factors are involved in treatment resistance. As no biological marker is available, clinical markers could be considered in predicting response to antidepressive treatment.
The aim of this study is to investigate the relation between the cognitive changes and the remission of depressive symptoms in patients with recurrent depression (Stage 2 of Thase and Rush classification).
To explore the dynamics of cognitive dimension associated to clinical and functional remission, the investigators will observe neurocognitive functioning before and after introducing a new antidepressive therapy.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Kontakter og lokationer
Studiesteder
-
-
-
Nice, Frankrig, 06000
- Hôpital Pasteur
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Prøveudtagningsmetode
Studiebefolkning
Beskrivelse
Inclusion Criteria:
- Patients will be aged from 40 to 70, with a major depressive episode diagnosis with a 2 stage degree of resistance.
Exclusion Criteria:
- Patients with major depressive episode during more of 12 months
- Alzheimer dementia or related disease (CIM 10)
- Score Hamilton Depression Rating Scale (HDRS) < 18
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Clinic assessments: Score BDI - II
Tidsramme: Change from the baseline score BDI-II at 12 months after introducing the new therapy
|
The investigators will conduct clinical assessments.
A baseline will be drawn in the acute phase (V1) before modifying the antidepressive therapy; 2 weeks after treatment change, patient will be clinically assessed by his psychiatrist.
A complete assessment will be done 6 months and 12 months after introducing the new therapy.
|
Change from the baseline score BDI-II at 12 months after introducing the new therapy
|
|
Functional assessments : Score Sheehan Disability Scale (SDS)
Tidsramme: Change from the baseline Score Sheehan Disability Scale (SDS) at 12 months after introducing the new therapy
|
The investigators will conduct functional assessments.
A baseline will be drawn in the acute phase (V1) before modifying the antidepressive therapy; 2 weeks after treatment change, patient will be functional assessed by his psychiatrist.
A complete assessment will be done 6 months and 12 months after introducing the new therapy.
|
Change from the baseline Score Sheehan Disability Scale (SDS) at 12 months after introducing the new therapy
|
|
Neuropsychologic assessments: M.M.S.E. (Mini Mental Score Evaluation)
Tidsramme: Change from the baseline Score M.M.S.E. (Mini Mental Score Evaluation) at 12 months after introducing the new therapy
|
The investigators will conduct neuropsychologic assessments.
A baseline will be drawn in the acute phase (V1) before modifying the antidepressive therapy; A complete assessment will be done 6 months and 12 months after introducing the new therapy.
|
Change from the baseline Score M.M.S.E. (Mini Mental Score Evaluation) at 12 months after introducing the new therapy
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Nelly Darmon, CHU of Nice
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Anslået)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 14-AOI-07
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .